{"schema":"hottub-news/story/v1","story":"st_5srwxlcatjcqhidujepq","title":"EADV 2026: Galderma's New Data Show Sustained Improvements with Nemluvio® (nemolizumab) for up to Three Years in Patients With Moderate-to-severe Atopic Dermatitis - Iberonews","title_en":null,"outlets":6,"brief":null,"page":"https://hottub.news/stories/eadv-2026-galdermas-new-data-show-sustained-improvements-with-nemluvio-5srwxlcatj","count":7,"items":[{"id":"n_7nneur7kb4cdhj76a4da","seq":876824,"kind":"article","title":"EADV 2026: Galderma's New Data Show Sustained Improvements with Nemluvio® (nemolizumab) for up to Three Years in Patients With Moderate-to-severe Atopic Dermatitis - Iberonews","url":"https://iberonews.com/not_det.php?lang=es&notid=110275","published":"2026-09-30T10:08:22Z","seen":"2026-09-30T10:08:22Z","lang":"en","source":{"id":"iberonews.com","name":"iberonews.com","domain":"iberonews.com"},"via":"gdelt-gkg-english","topics":["science"],"entities":[{"id":"Q581008","name":"Galderma","type":"org"}],"story":"st_5srwxlcatjcqhidujepq","category":"health","category_p":0.49000000953674316,"category2":"economy-business","sentiment":"positive","tone":0.3400000035762787,"political":0.03999999910593033},{"id":"n_6j52bf6s3cm4wvdbzwiq","seq":865536,"kind":"article","title":"Galderma Reports Three-Year Nemluvio Data In Moderate-to-Severe Atopic Dermatitis","url":"https://www.rttnews.com/3695057/galderma-reports-three-year-nemluvio-data-in-moderate-to-severe-atopic-dermatitis.aspx","published":"2026-09-30T06:00:00Z","seen":"2026-09-30T09:13:21Z","lang":"en","source":{"id":"rttnews.com","name":"rttnews.com","domain":"rttnews.com","outlet":{"wikidata":"Q60748698","name":"RTTNews","type":"news_agency","designations":["news agency","news website"]}},"via":"gdelt-gkg-english","topics":["economy","business","health","politics"],"entities":[{"id":"Q581008","name":"Galderma","type":"org"}],"story":"st_5srwxlcatjcqhidujepq","category":"health","category_p":0.38999998569488525,"sentiment":"neutral","tone":-0.36000001430511475,"political":0.029999999329447746},{"id":"n_b3snadvwci5spm3hw4vq","seq":835203,"kind":"article","title":"Galderma's Nemluvio Shows Sustained Three-Year Benefits In Atopic Dermatitis","url":"https://www.rttnews.com/3695051/galderma-s-nemluvio-shows-sustained-three-year-benefits-in-atopic-dermatitis.aspx","published":"2026-09-30T05:44:00Z","seen":"2026-09-30T06:05:48Z","lang":"en","source":{"id":"rttnews.com","name":"rttnews.com","domain":"rttnews.com","outlet":{"wikidata":"Q60748698","name":"RTTNews","type":"news_agency","designations":["news agency","news website"]}},"via":"gdelt-gkg-english","topics":["economy","politics"],"entities":[{"id":"Q581008","name":"Galderma","type":"org"}],"story":"st_5srwxlcatjcqhidujepq","category":"health","category_p":0.49000000953674316,"sentiment":"positive","tone":0.1599999964237213,"political":0.019999999552965164},{"id":"n_5srwxlcatjcqhidujepq","seq":833486,"kind":"article","title":"EADV 2026: Galderma's New Data Show Sustained Improvements with Nemluvio® (nemolizumab) for up to Three Years in Patients With Moderate-to-severe Atopic Dermatitis","url":"https://www.intelligencer.ca/press-releases/business-wire/eadv-2026-galdermas-new-data-show-sustained-improvements-with-nemluvio-nemolizumab-for-up-to-three-years-in-patients-with-moderate-to-severe-atopic-dermatitis","published":"2026-09-30T05:04:00Z","seen":"2026-09-30T05:53:01Z","lang":"en","country":"CA","source":{"id":"intelligencer.ca","name":"intelligencer.ca","domain":"intelligencer.ca","outlet":{"wikidata":"Q4883859","name":"Belleville Intelligencer","type":"magazine","country":"CA","designations":["periodical"]}},"via":"gdelt-gkg-english","topics":["economy","politics","education","science"],"authors":["Business Wire"],"story":"st_5srwxlcatjcqhidujepq","category":"health","category_p":0.6000000238418579,"sentiment":"positive","tone":0.14000000059604645,"political":0.019999999552965164},{"id":"n_p7wnbjv7alzu5yqqek4q","seq":835140,"kind":"article","title":"EADV 2026: Galderma's New Data Show Sustained Improvements with Nemluvio® (nemolizumab) for up to Three Years in Patients With Moderate-to-severe Atopic Dermatitis","url":"https://www.recorder.ca/press-releases/business-wire/eadv-2026-galdermas-new-data-show-sustained-improvements-with-nemluvio-nemolizumab-for-up-to-three-years-in-patients-with-moderate-to-severe-atopic-dermatitis","published":"2026-09-30T05:04:00Z","seen":"2026-09-30T06:05:48Z","lang":"en","country":"CA","source":{"id":"recorder.ca","name":"recorder.ca","domain":"recorder.ca"},"via":"gdelt-gkg-english","topics":["economy","health","education","politics"],"authors":["Business Wire"],"entities":[{"id":"Q581008","name":"Galderma","type":"org"},{"id":"Q268667","name":"atopic dermatitis","type":"other"}],"story":"st_5srwxlcatjcqhidujepq","category":"health","category_p":0.6000000238418579,"sentiment":"positive","tone":0.14000000059604645,"political":0.019999999552965164},{"id":"n_ehbuctqu3mtbe6eho4xa","seq":835383,"kind":"article","title":"EADV 2026: Galderma's New Data Show Sustained Improvements with Nemluvio® (nemolizumab) for up to Three Years in Patients With Moderate-to-severe Atopic Dermatitis","url":"https://www.standard-freeholder.com/press-releases/business-wire/eadv-2026-galdermas-new-data-show-sustained-improvements-with-nemluvio-nemolizumab-for-up-to-three-years-in-patients-with-moderate-to-severe-atopic-dermatitis","published":"2026-09-30T05:04:00Z","seen":"2026-09-30T06:05:48Z","lang":"en","source":{"id":"standard-freeholder.com","name":"standard-freeholder.com","domain":"standard-freeholder.com"},"via":"gdelt-gkg-english","topics":["economy","education","health","politics"],"authors":["Business Wire"],"entities":[{"id":"Q581008","name":"Galderma","type":"org"},{"id":"Q268667","name":"atopic dermatitis","type":"other"}],"story":"st_5srwxlcatjcqhidujepq","category":"health","category_p":0.6000000238418579,"sentiment":"positive","tone":0.14000000059604645,"political":0.019999999552965164},{"id":"n_t6pdyzs5c5s4gs5vuiha","seq":844261,"kind":"article","title":"EADV 2026: Galderma's New Data Show Sustained Improvements with Nemluvio® (nemolizumab) for up to Three Years in Patients With Moderate-to-severe Atopic Dermatitis","url":"https://www.thewhig.com/press-releases/business-wire/eadv-2026-galdermas-new-data-show-sustained-improvements-with-nemluvio-nemolizumab-for-up-to-three-years-in-patients-with-moderate-to-severe-atopic-dermatitis","published":"2026-09-30T05:04:00Z","seen":"2026-09-30T07:14:32Z","lang":"en","source":{"id":"thewhig.com","name":"thewhig.com","domain":"thewhig.com","outlet":{"wikidata":"Q928635","name":"Kingston Whig-Standard","type":"newspaper","country":"CA","designations":["daily newspaper"]}},"via":"gdelt-gkg-english","topics":["economy","education","health","politics"],"authors":["Business Wire"],"entities":[{"id":"Q581008","name":"Galderma","type":"org"},{"id":"Q30314619","name":"nemolizumab","type":"other"},{"id":"Q268667","name":"atopic dermatitis","type":"other"}],"story":"st_5srwxlcatjcqhidujepq","category":"health","category_p":0.6000000238418579,"sentiment":"positive","tone":0.14000000059604645,"political":0.019999999552965164}]}